Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%.
The iShares Biotechnology ETF (IBB) shed 0.7%.
In corporate news, Merck (MRK) secured exclusive rights to develop and sell an oral weight loss drug under a license deal with Hansoh Pharma that could fetch the Chinese biopharmaceutical company up to $2 billion. Merck shares were down 0.3%.
Cognition Therapeutics (CGTX) shares surged 67% after it said Wednesday that a phase 2 trial of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.
KalVista Pharmaceuticals' (KALV) drug candidate sebetralstat is a promising, on-demand oral treatment for hereditary angioedema that demonstrated efficacy comparable to approved injectables with the added convenience of oral dosing in a phase 3 study, BofA Securities said in a note. The firm started coverage of KalVista with a buy rating and a price objective of $22. KalVista shares popped 2.2%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。